Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095342 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating TMI-005 in Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 390
- Enrollment target
NCT00095342: Completed Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00095342 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 390 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (193% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00095342, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 390 participants
- Enrollment target
Study Summary
The primary objective of this clinical research study is to compare the efficacy and the safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active Rheumatoid Arthritis (RA) who have been receiving stable doses of Methotrexate (MTX).
Interventions
- DRUG TMI-005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00095342 record still lists
NCT00095342 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (193% higher).
The record links to 0 conditions, and to 1 intervention - of which TMI-005 is the first listed.
NCT00095342 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00095342 about?
NCT00095342 is a clinical study titled "Study Evaluating TMI-005 in Active Rheumatoid Arthritis". The primary objective of this clinical research study is to compare the efficacy and the safety of 3 dose levels of oral TMI-005 in comparison with placebo in subjects with active Rheumatoid Arthritis (RA) who have been receiving stable doses of Methotrexate (MTX).
What is the current status of trial NCT00095342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 390 participants. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00095342?
The interventions under investigation include: TMI-005 (DRUG).
Who is sponsoring clinical trial NCT00095342?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00095342's enrollment target sits among peer trials
390 106th of 2000 higher than 1,893 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer